A new antibody has been developed to block immune suppression in aggressive breast cancer, offering a promising treatment.
Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 1 μg/mL (100 μL/well) can bind Anti-CD3 antibody with a linear range of 0.2–6 ng/mL. Image Credit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback